Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.

cancer ibrutinib invasive fungal infections opportunistic infections small molecule kinase inhibitors

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
25 08 2022
Historique:
received: 01 11 2021
pubmed: 12 12 2021
medline: 30 8 2022
entrez: 11 12 2021
Statut: ppublish

Résumé

We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).

Identifiants

pubmed: 34893821
pii: 6459159
doi: 10.1093/cid/ciab1026
pmc: PMC9184298
mid: NIHMS1771626
doi:

Substances chimiques

Piperidines 0
ibrutinib 1X70OSD4VX
Adenine JAC85A2161

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

334-337

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Déclaration de conflit d'intérêts

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

Curr Fungal Infect Rep. 2019 Sep;13(3):86-98
pubmed: 31555394
Clin Infect Dis. 2018 Aug 16;67(5):687-692
pubmed: 29509845
Blood. 2018 Jan 25;131(4):379-386
pubmed: 29255067
Blood. 2018 Apr 26;131(17):1955-1959
pubmed: 29437588
Future Sci OA. 2018 Jun 14;4(6):FSO307
pubmed: 30057784
Nat Rev Drug Discov. 2021 Nov;20(11):839-861
pubmed: 34354255
Mycoses. 2019 Dec;62(12):1140-1147
pubmed: 31520441
Clin Infect Dis. 2018 Jan 6;66(1):140-148
pubmed: 29029010
Ann Hematol. 2020 Jul;99(7):1429-1440
pubmed: 32514626
J Infect Chemother. 2021 Dec;27(12):1700-1705
pubmed: 34389223

Auteurs

Jeremy A W Gold (JAW)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Seda S Tolu (SS)

Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA.

Tom Chiller (T)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Kaitlin Benedict (K)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Brendan R Jackson (BR)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH